Jaimy Lee

Plus, news about Pep­Gen and Jasper Ther­a­peu­tics: Jazz Phar­ma­ceu­ti­cals buys Redx Phar­ma’s KRAS in­hibitors: The com­pa­ny is pay­ing Redx $10 mil­lion up­front, with mile­stones up

Plus, news about At­tralus, Sang­amo, Mithra, NeOnc, 4D Mol­e­c­u­lar Ther­a­peu­tics and Im­mix Bio­phar­ma: Im­munome buys Ay­ala’s desmoid tu­mor as­set: The biotech will pay $20 mil­lion

Plus, news about An­bo­gen Ther­a­peu­tics and Ve­ra Ther­a­peu­tics: Hutchmed inks deal of up to $227.5M: The com­pa­ny is li­cens­ing two drugs to Im­ma­gene Bio­phar­ma­ceu­ti­cals: IMG-007,

Plus, news about Cor­bus and Astel­las: Halia Ther­a­peu­tics rais­es $30M Se­ries C: The com­pa­ny, which is de­vel­op­ing small mol­e­cules for in­flam­ma­to­ry dis­eases, plans to use

Plus, news about Skye Bio­science and Ve­ra Ther­a­peu­tics: As­cendis Phar­ma, in­vestors spin out eye care com­pa­ny: Ey­co­nis, based in Red­wood City, CA, will de­vel­op, man­u­fac­ture

Plus, news about Prime Med­i­cine, Sagimet Bio­sciences and Adicet Bio: Deer­field ter­mi­nates rights to 2017 deal with Windtree Ther­a­peu­tics: The biotech last year in-li­censed Aero­surf,

Plus, news about Ve­ra Ther­a­peu­tics and Cel­lec­tar Bio­sciences: Al­pham­ab On­col­o­gy, Glen­mark ink li­cens­ing deal: Per the agree­ment, Glen­mark will spend up to $700.8 mil­lion in

PMV Phar­ma­ceu­ti­cals to cut 30% of its em­ploy­ees: The Prince­ton, NJ-based com­pa­ny had 62 full-time em­ploy­ees as of Feb. 28. It ex­pects the cuts to ex­tend

Plus, news about Pro­ta Ther­a­peu­tics and Vaxart: Windtree Ther­a­peu­tics inks deal with Hong Kong group: Per the terms, Lee’s Phar­ma­ceu­ti­cal will pay Windtree up to

Ji Xing ac­quires Bio­gen’s ex­per­i­men­tal ther­a­py for acute is­chemic stroke: The Shang­hai-based bio­phar­ma did not dis­close the fi­nan­cial terms of the deal. Back in 2018,